Type 2 diabetes and coronary heart disease: We keep learning how little we know

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 6, 2003, Pages 917-918

  Reaven, Gerald ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; ORAL ANTIDIABETIC AGENT;

ATHEROGENESIS; CARDIOVASCULAR RISK; CAROTID ARTERY; COMMON CAROTID ARTERY; DIABETES CONTROL; DISEASE COURSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; EDITORIAL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MORALITY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ARTERIOSCLEROSIS; CAROTID STENOSIS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 0038797872     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000077249.35122.19     Document Type: Editorial

References (8)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
3. Wangenknecht LE, Zaccaro MS, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 2002;23:1035-1041.
4. Zoccali C, Bode-Boger SM, Maallamaci F, Benedetto FM, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Fermo I, Frolich JC, Boger RH. Plasma concentration asymmetrical dimethylarginine and mortality in patients with end-state renal disease: a prospective study. Lancet. 2001;358:2113-2117.
5. Abbasi F, Asagami T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Steuhlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes. Am J Cardiol. 2001;88:1201-1203.
6. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis RB, Cole TG, Pfeffer MA, Braunwald E, for the Care Investigators. Cardiovascular events and their reductions with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the Cholesterol and Recurrent Events (CARE) Trial. Circulation. 1998;98:2513-2519.
7. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K, for the Scandinavian Simvastatin Survival Study Group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis of the Scandinavian Simvastatin Survival Study. Arch Int Med. 1999;159:2661-2667.
8. Lehto S, Ronnemaa T, Pyorala K, Laasko M. Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia. 2000;43:148-155.